Real-World Study Confirms Pfizer-BioNTech mRNA Vaccine BNT162b2 Maintains 94% Efficacy Against Symptomatic COVID-19, Aligning with Clinical Trial Results

On February 25, real-world data on the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 showed that its efficacy in preventing symptomatic COVID-19 was 94% after two doses, consistent with clinical trial results. The study analyzed and compared COVID-19 outcomes among nearly 600,000 vaccinated and unvaccinated individuals. The research paper was published in the New England Journal of Medicine (NEJM) in the early hours of February 25 (Beijing time).